VivoSeq
Hematology

G6PD Deficiency

0

Pipeline Programs↗

0

Active Trials↗

1

Companies Involved↗

G6PD Deficiency is an early-stage landscape with 0 programs across 1 company. The most active players are AbbVie.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

80/100

Attrition Rate

20/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AbbVie logo

AbbVie

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

5

clinical trials

Completed4 · 80%
Terminated1 · 20%

Clinical Trials

Trial Activity

Assessing a Risk Model for G6PD Deficiency
Terminated·PPATH·Phase 4·NCT03337152·54 enrolled
A Test to Predict the Hemolytic Potential of Drugs in G6PD Deficiency
Completed·WWalter Reed Army Institute of Research (WRAIR)·N/A·NCT00076323·14 enrolled
Phase IV Study to Gather More Information About the Safety of ACZONE Gel, 5% in Treating Subjects With Acne Who Have G6PD Deficiency
Completed·AbbVie logoAbbVie·Phase 4·NCT00243542·64 enrolled
Pharmacokinetic and in Vitro Transmission Blocking Activities Study of Primaquine Compare to Methylene Blue in Healthy Volunteer Both G6PD Normal and G6PD Deficiency
Completed·UUniversity of Oxford·Phase 1·NCT01668433·20 enrolled
Effect of G6PD Deficiency on Red Blood Cell Storage
Completed·—·N/A·NCT04081272·40 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)